利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.031 秒)

    COMBINATION OF VACCINATION AND INHIBITION OF MHC CLASS I RESTRICTED ANTIGEN PRESENTATION
    1.
    发明申请
    COMBINATION OF VACCINATION AND INHIBITION OF MHC CLASS I RESTRICTED ANTIGEN PRESENTATION 审中-公开
    MHC类限制性抗原呈递的组合和抑制

    公开(公告)号：WO2012089225A1

    公开(公告)日：2012-07-05

    申请号：PCT/EP2010/007969

    申请日：2010-12-29

    申请人： CUREVAC GMBH ,  LORENZ, Christina ,  FOTIN-MLECZEK, Mariola ,  KALLEN, Karl-Josef

    发明人： LORENZ, Christina ,  FOTIN-MLECZEK, Mariola ,  KALLEN, Karl-Josef

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P31/12

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516

    摘要： The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. The present invention also provides kit of parts comprising the inventive vaccine/inhibitor combination, preferably in different parts of the kit, e.g. for prior, concurrent or subsequent administration of the different parts. Additionally the invention relates to a pharmaceutical composition comprising the inventive vaccine/inhibitor combination to further improve the immune response against tumour cells and infected cells having lost the capability of MHC class I restricted antigen presentation.

    摘要翻译： 本发明涉及疫苗/抑制剂组合，其包含作为至少一种抗原的疫苗和作为主要组织相容性复合物（MHC）I类限制性抗原呈递的至少一种抑制剂的抑制剂。 本发明还涉及使用本发明的疫苗/抑制剂组合接种哺乳动物的方法。 本发明还提供了包含本发明的疫苗/抑制剂组合的部分试剂盒，优选在试剂盒的不同部分，例如， 用于先前，并发或后续管理不同部件。 另外，本发明涉及包含本发明的疫苗/抑制剂组合的药物组合物，以进一步改善针对肿瘤细胞的免疫应答和已失去MHC I类限制性抗原呈递能力的感染细胞。

    COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION
    6.
    发明申请
    COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION 审中-公开
    用转移和免疫接种的交联中和组分的核酸复合物

    公开(公告)号：WO2012013326A1

    公开(公告)日：2012-02-02

    申请号：PCT/EP2011/003719

    申请日：2011-07-25

    申请人： CUREVAC GMBH ,  BAUMHOF, Patrick ,  VOSS, Söhnke ,  KRAMPS, Thomas ,  KALLEN, Karl-Josef

    发明人： BAUMHOF, Patrick ,  VOSS, Söhnke ,  KRAMPS, Thomas ,  KALLEN, Karl-Josef

    IPC分类号： C12N15/87 ,  A61K48/00 ,  A61K47/34 ,  A61K47/48

    CPC分类号： A61K48/0041 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K47/645 ,  A61K2039/51 ,  A61K2039/55516 ,  A61K2039/55561 ,  C12N15/87 ,  Y02A50/412 ,  Y02A50/472

    摘要： The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned above. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and/or the inventive pharmaceutical composition, adjuvant or vaccine in one or more parts of the kit.

    摘要翻译： 本发明涉及一种聚合物载体货物复合物，其包含至少一种核酸（分子）和作为（优选无毒的和非免疫原性的）聚合物载体的二硫键交联的阳离子组分。 本发明的聚合物载体货物复合物允许在体内和体外有效地将核酸转染到细胞中和/或诱导（先天和/或自适应）免疫应答，优选依赖于作为货物运输的核酸 。 本发明还提供药物组合物，特别是疫苗和佐剂，其包含本发明的聚合物载体货物复合物和任选的抗原，以及使用本发明的本发明的聚合物载体货物复合物和任选的抗原用于转染细胞，组织 或用于本文公开的（基因 - ）治疗目的的生物体，和/或作为免疫刺激剂或佐剂，例如， 用于引发用于治疗或预防上述疾病的免疫应答。 最后，本发明涉及在试剂盒的一个或多个部分中含有本发明的聚合物载体货物复合物和/或本发明的药物组合物，佐剂或疫苗的试剂盒。

    CANCER TREATMENTS WITH RADIATION AND IMMUNOCYTOKINES
    7.
    发明申请
    CANCER TREATMENTS WITH RADIATION AND IMMUNOCYTOKINES 审中-公开
    癌症治疗与辐射和免疫球蛋白

    公开(公告)号：WO2010046097A1

    公开(公告)日：2010-04-29

    申请号：PCT/EP2009/007533

    申请日：2009-10-21

    申请人： MERCK PATENT GmbH ,  WICKHAM, Thomas ,  GNAD-VOGT, Ulrike ,  KLINZ, Stephan G. ,  HOLDEN, Sylvia A. ,  KALLEN, Karl Josef

    发明人： WICKHAM, Thomas ,  GNAD-VOGT, Ulrike ,  KLINZ, Stephan G. ,  HOLDEN, Sylvia A. ,  KALLEN, Karl Josef

    IPC分类号： A61K38/20

    CPC分类号： A61K38/2013 ,  A61K38/208 ,  A61N5/10

    摘要： The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy.

    摘要翻译： 本发明涉及通过在放射治疗后施用免疫细胞因子来治疗肿瘤和癌细胞的方法。 这种治疗组合可以刺激照射和非照射部位的免疫应答，这对于根除从原发肿瘤部位扩散的癌细胞是有用的。 此外，免疫细胞因子可以以小于最大耐受剂量的剂量施用，这降低了与免疫细胞因子疗法相关的副作用。

    ARTIFICIAL NUCLEIC ACID MOLECULES
    10.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES 审中-公开
    人工核酸分子

    公开(公告)号：WO2013143698A1

    公开(公告)日：2013-10-03

    申请号：PCT/EP2013/000936

    申请日：2013-03-27

    申请人： CUREVAC GMBH ,  THESS, Andreas ,  KALLEN, Karl-Josef

    发明人： THESS, Andreas ,  KALLEN, Karl-Josef

    IPC分类号： C12N15/67 ,  C12N15/85

    CPC分类号： C12N15/85 ,  A61K48/00 ,  C12N15/67 ,  C12N15/88 ,  C12N2830/50

    摘要： The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'UTR element comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3'UTR element comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3'UTR element.

    摘要翻译： 本发明涉及包含至少一个开放阅读框和至少一个3'UTR元件的人源核酸分子，其包含衍生自白蛋白基因的3'UTR或3'UTR的变体的核酸序列 的白蛋白基因。 本发明还涉及这种人工核酸分子在基因治疗和/或基因疫苗接种中的用途。 此外，本发明涉及包含衍生自白蛋白基因的3'UTR或白蛋白基因的3'UTR的变体的核酸序列的3'UTR元件用于稳定化和/或 从包含这种3'UTR元件的核酸序列延长蛋白质表达。